Replies to post #130092 on Biotech Values

[DewDiligence]

TEVA said it would be "premature" to submit an NDA at this time for laquinimod and will be working with FDA to design an additional trial…

I don’t think it’s too soon to say that Laquinimod will never to amount to anything of great consequence. Even in the best-case scenario for Teva, it will be a day late and a dollar short.